Studies on Hypercoagulable State

Summary

The rate of disappearance of ¹³¹I-labelled, purified fibrinogen was estimated in 43 human subjects simultaneously with repeated determinations of various other constituents of the coagulation and fibrinolytic systems.

A marked shortening of theT/2 of ¹³¹I-labelled fibrinogen was observed in patients with thromboembolic disease, as well as in some patients following extensive surgical procedures, in the absence of clinical signs of occlusive vascular lesions at the time of the study. In some of the latter patients thromboembolic episodes developed subsequently.

The application of the procedures described here in the diagnosis of the so-called hypercoagulable state is discussed.

• References

• 1 Aas K. A, Gardner F. H. Survival of blood platelets labeled with chromium. J. clin. Invest 37: 1257 1958;
• 2 Adelson E, Rheingold J. J, Crosby W. H. Studies on platelets survival by tagging in vivo with P³² . J. Lab. Clin. Med. 50: 570 1957;
• 3 Leeksma C. H. W, Cohen J. A. Determination of the life span of human blood platelets using labelled diisopropyl-fluorophosphate. J. clin. Invest 35: 964 1956;
• 4 Izah G, Galewski K. Studies on experimentally induced hypercoagulable state in rabbits. Thrombos. Diathes. hacmorrh. (Stuttg.). 16: 228 1966;
• 5 Zetterquist E, Blombäck B, Carlson L. A, Franzen S. The turnover of I¹³¹ labelled fibrinogen in man. p. G: 77. Xth Cong. Int. Soc. Haemat. Stockholm: Ljunghofs Litografiska A. AB; 1964
• 6 Tocantins L. M. The bleeding time. Amer. J. clin. Path. 06: 160 1936;
• 7 Lee R. I, White P. D. A clinical study of the coagulation time of blood. Amer. J. med. Sci. 35: 964 1913;
• 8 Budtz-Olsen O. E. Clot retraction. Blackwell Scientific Publications; Oxford: 1951
• 9 Wintrobe M. M. Clinical Haematology. 299 Henry Kimpton; London: 1961
• 10 Quick A. T. Determination of prothrombin. In: Quick A. J. The physiology and pathology of hemostasis. 125 Lea and Fabiger; Philadelphia: 1951
• 11 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path. 19: 471 1949;
• 12 Stefanini: New on-stage procedure for the quantitative determination of prothrombin and labile factor. Amer. J. clin. Path. 20: 233 1950;
• 13 Alexander B. Clotting factor VII (proconvertin) Synonymy properties and clinical-laboratory aspects. New Engl. J. Med. 260: 1218 1959;
• 14 Bachmann F, Duckert F, Koller F. Stewart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. (Stuttg.). 02: 24 1958;
• 15 Ratnoff O. D, Menzie C. A new method for determination of fibrinogen in small samples of plasma. J. Lab. clin. Med. 37: 316 1951;
• 16 Von Kaulla K. N, Schultz R. L. Methods for evaluation of human fibrinolysis. Amer. J. clin. Path. 29: 104 1958;
• 17 Astrujp A. T. The biological significance of fibrinolysis. Lancet II: 565 1956;
• 18 Nestel P. J. A note on platelet adhesiveness in ischemic heart disease. J. clin. Path. 14: 150 1961;
• 19 Wright H. P. Venous thrombosis during pregnancy treated with dicoumarin. J. Obstet. Gynaec. Brit. Emp. 58: 273 1951;
• 20 Fearnley G. R. In: Fibrinolysis. 145 Edward Arnold Ltd; London: 1965
• 21 Izak G, Galewski K, Eyal Z. Hypercoagulable state. Proc. IIIrd. Cong. Asian-Pacific Soc. Hemat. Israel J. med. Sci. 1965
• 22 Gajewski Y, Alexander B. Effect of epsilon aminocaproic acid on turnover of labelled fibrinogen. Circ. Res. 13: 432 1963;